Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

World Health Organization, Solid Tumors, Cancer Management +17

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

Phase II Study of Imatinib in Advanced Chordoma

Silvia Stacchiotti, Alessandra Longhi, Virginia Ferraresi et al. · Journal of Clinical Oncology · 2012 · 264 citations · Full text

Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers

Silvia Stacchiotti, Paolo G. Casali, Salvatore Lo Vullo et al. · Annals of Surgical Oncology · 2009 · 191 citations

Referral Centers, Spinal Cord Injury, Retrospective Analysis +9

Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)

Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Bompas et al. · The Oncologist · 2012 · 187 citations · Full text